Actively Recruiting
Phase III Study of MBS303 Treatment for Adults with Relapsed or Refractory CD20 B-Cell Non-Hodgkins Lymphoma
Led by Beijing Mabworks Biotech Co., Ltd. · Updated on 2024-11-20
132
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying a novel T-Cell bispecific drug called MBS303 in adults with relapsed or refractory CD20-positive B-cell Non-Hodgkin Lymphoma NHL who have not responded to prior anti-CD20 monoclonal antibody treatment. This Phase III multicenter, open-label study aims to evaluate the safety, tolerability, how the drug moves and acts in the body pharmacokinetics and pharmacodynamics, and its effectiveness against the disease. The study is sponsored by Beijing Mabworks Biotech Co., Ltd. and includes two main parts dose escalation Phase I and dose expansion Phase II.
CONDITIONS
Brief Title
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Research Team
Y
Yuqin Song, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
